By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ACT Biotech 

717 Market Street
Suite 650
San Francisco  California  94103  U.S.A.
Phone: 415-230-3900 Fax: 415-230-3950




Company News
Week in Review: Eddingpharm (Cayman) Inc. Buys ACT Biotech Assets For $95 Million 1/13/2014 8:50:25 AM
Eddingpharm (Cayman) Inc. Acquired Global Rights To Oncology Assets, Including Telatinib, From ACT Biotech 1/8/2014 10:02:49 AM
ACT Biotech Release: Telatinib Effect on Biomarker is Associated With More Than Six Months Improvement in Progression-Free Survival for Stomach Cancer Patients 11/14/2011 9:59:34 AM
ACT Biotech's Telatinib Demonstrates Significant Progress in Stomach Cancer Treatment; Phase 2 Data to be Presented at American Society of Clinical Oncology 6/2/2011 10:14:49 AM
ACT Biotech to Present Significant Progress in Stomach Cancer Treatment at American Society of Clinical Oncology 5/19/2011 10:00:20 AM
ACT Biotech Files Special Protocol Assessment With FDA for Phase 3 Trial of Telatinib for Front-Line Treatment of Stomach Cancer 2/28/2011 9:47:26 AM
ACT Biotech Release: Phase 2 Data in Stomach Cancer Show Telatinib's Potent Antiangiogenic Activity 1/20/2011 12:35:54 PM
ACT Biotech Announces Positive Interim Phase 2 Results with Telatinib in First-line Gastric Cancer 10/11/2010 11:10:52 AM
ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and Highly Selective Kinase Inhibitor, in Gastric Cancer 6/2/2010 10:15:19 AM
ACT Biotech Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic 1/22/2010 9:39:25 AM